Literature DB >> 15115769

Purification and characterization of recombinant human prostacyclin synthase.

Masayuki Wada1, Chieko Yokoyama, Toshihisa Hatae, Manabu Shimonishi, Masahiko Nakamura, Yoshio Imai, Volker Ullrich, Tadashi Tanabe.   

Abstract

Prostacyclin synthase (PGIS), which catalyzes the conversion of prostaglandin (PG) H(2) to prostacyclin (PGI(2)), is a member of the cytochrome P-450 (P450) superfamily, CYP8A1. To study the enzymatic and protein characteristics of human PGIS, the enzyme was overexpressed in Spodoptera frugiperda 21 (Sf21) cells using the baculovirus expression system. PGIS was expressed in the microsomes of the infected Sf21 cells after culture in 5 microg/ml hematin-supplemented medium for 72 h. The holoenzyme was isolated from the solubilized microsomal fraction by calcium phosphate gel absorption and purified to homogeneity by DEAE-Sepharose and hydroxyapatite column chromatography. The K(m) and V(max) values of the purified human PGIS for PGH(2) were 30 microM and 15 micromol/min/mg of protein at 24 degrees C, respectively. The optical absorption and EPR spectra of the enzyme revealed the characteristics of a low-spin form of P450 in the oxidized state. The carbon monoxide-reduced difference spectrum, however, exhibited a peak at 418 nm rather than 450 nm. The addition of a PGH(2) analogue, U46619, to the enzyme produced an oxygen-ligand type of the difference spectrum with maximum absorption at 407 nm and minimum absorption at 430 nm. Treatment with another PGH(2) analogue, U44069, produced a peak at 387 nm and a trough at 432 nm in the spectrum (Type I), while treatment with tranylcypromine, a PGIS inhibitor, produced a peak at 434 nm and a trough at 412 nm (Type II). A Cys441His mutant of the enzyme possessed no heme-binding ability or enzyme activity. Thus, we succeeded in obtaining a sufficient amount of the purified recombinant human PGIS from infected insect cells for spectral analyses that has high specific activity and the characteristics of a P450, indicating substrate specificity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115769     DOI: 10.1093/jb/mvh059

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  10 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

Review 3.  Prostaglandin E3 metabolism and cancer.

Authors:  Peiying Yang; Yan Jiang; Susan M Fischer
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

Review 4.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

5.  Characterization of heme environment and mechanism of peroxide bond cleavage in human prostacyclin synthase.

Authors:  Hui-Chun Yeh; Pei-Yung Hsu; Jinn-Shyan Wang; Ah-Lim Tsai; Lee-Ho Wang
Journal:  Biochim Biophys Acta       Date:  2005-12-20

6.  Large-scale expression, purification, and characterization of an engineered prostacyclin-synthesizing enzyme with therapeutic potential.

Authors:  Ke-He Ruan; Shui-Ping So; Hanjing Wu; Vanessa Cervantes
Journal:  Arch Biochem Biophys       Date:  2008-09-22       Impact factor: 4.013

7.  Major urinary metabolites of 6-keto-prostaglandin F2α in mice.

Authors:  Dmitry V Kuklev; Joseph A Hankin; Charis L Uhlson; Yu H Hong; Robert C Murphy; William L Smith
Journal:  J Lipid Res       Date:  2013-05-03       Impact factor: 5.922

Review 8.  The enzymology of the human prostanoid pathway.

Authors:  Roger Gregory Biringer
Journal:  Mol Biol Rep       Date:  2020-05-19       Impact factor: 2.316

9.  Protein tyrosine nitration and thiol oxidation by peroxynitrite-strategies to prevent these oxidative modifications.

Authors:  Andreas Daiber; Steffen Daub; Markus Bachschmid; Stefan Schildknecht; Matthias Oelze; Sebastian Steven; Patrick Schmidt; Alexandra Megner; Masayuki Wada; Tadashi Tanabe; Thomas Münzel; Serge Bottari; Volker Ullrich
Journal:  Int J Mol Sci       Date:  2013-04-08       Impact factor: 5.923

10.  Selective inhibition of prostacyclin synthase activity by rofecoxib.

Authors:  Cristiana Griffoni; Enzo Spisni; Antonio Strillacci; Mattia Toni; Markus Michael Bachschmid; Vittorio Tomasi
Journal:  J Cell Mol Med       Date:  2007 Mar-Apr       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.